Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Ghanshyam Biswas; Avinash Pandey; Nikhil Ghadyalpatil; Nilesh Lokeshwar; Boben Thomas; Anita Ramesh; Yogesh Arora; Chandragouda Dodagoudar; Vibha Naik; Ashish Joshi; Indranil Ghosh; Rakesh Roy; Medhi Kunjahari; Tejinder Singh; Palanki Dattatreya Satya; Sachin Hingmire; Purvish M. Parikh

doi:10.4103/sajc.sajc_246_19

South Asian Journal of Cancer, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · South Asian J Cancer 2020; 09(01): 59-61
DOI: 10.4103/sajc.sajc_246_19

ORIGINAL ARTICLE: Supportive Care and Others

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Autor*innen

Ghanshyam Biswas

Department of Medical Oncology, Sum Hospital, Bhubaneswar, Odisha
Avinash Pandey

Department of Medical Oncology, RCC, Patna, Bihar
Nikhil Ghadyalpatil

Department of Medical Oncology, Yashoda Hospital, Secunderabad, Telangana
Nilesh Lokeshwar

Department of Medical Oncology, Asian Cancer Institute, Mumbai, Maharashtra
Boben Thomas

Department of Medical Oncology, Kerala Institute of Medical Sciences, Trivandrum, Kerala
Anita Ramesh

Department of Medical Oncology, Apollo Specialty Hospital, Chennai, Tamil Nadu
Yogesh Arora

Department of Medical Oncology, Mohandai Oswal Hospital, Ludhiana, Punjab
Chandragouda Dodagoudar

Department of Medical Oncology, BLK Superspeciality Hospital, Delhi, NCR
Vibha Naik

Department of Medical Oncology, Naik Hospital, Baroda, Gujarat
Ashish Joshi

Department of Medical Oncology, Mumbai Oncocare Center, Mumbai, Maharashtra
Indranil Ghosh

Department of Medical Oncology, Apollo Hospital, Kolkata, West Bengal
Rakesh Roy

Department of Pain and Palliative Care, Saroj Gupta Cancer Hospital, Kolkata, West Bengal
Medhi Kunjahari

Department of Medical Oncology, Batra Cancer Center, Delhi, NCR
Tejinder Singh

Department of Medical Oncology, Fortis Hospital, Mumbai, Maharashtra
Palanki Dattatreya Satya

Department of Medical Oncology, Omega Hospital, Hyderabad, Telangana
Sachin Hingmire

Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra
Purvish M. Parikh

Department of Medical Oncology, Shalby Cancer and Research Institute, Ahmedabad, Gujarat

Abstract

als PDF herunterladen

Abstract

Introduction: Anemia is a common, underestimated problem in cancer patients receiving myelosuppressive chemotherapy and has significant adverse effect on the quality of life and outcome. Darbepoetin has been shown to be effective in this setting, but controversy surrounds it actual use. Methods: We analyzed prospectively collected clinical practice data of patients receiving darbepoetin in a real-world setting for this retrospective audit. Patients with baseline hemoglobin (Hb) of <11 g/dl were included in this analysis. Their medical records were audited using a predetermined 35-point pro forma. Results: There were a total of 274 patients with advanced cancer receiving myelosuppressive chemotherapy who had baseline Hb <11 g/dl and who were given darbepoetin. Head-and-neck squamous cell carcinoma, lung cancer, and breast cancer were the most common cancers. Their median baseline Hb was 8.9 g/dl which rose to 11.2 g/dl at the end of commenced therapy, along with improved symptomatology. There were no new toxicities, and only two patients required discontinuation of darbepoetin due to toxicity. Conclusion: Darbepoetin is safe and effective in the prevention and management of anemia among patients receiving myelosuppressive chemotherapy.

Key words

Hemoglobin - India - prophylaxis - quality of life - quality of life

PDF (444 kb)

Referenzen

References
1 Barrett-Lee PJ, Ludwig H, Birgegård G, Bokemeyer C, Gascón P, Kosmidis PA, et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: Results from the European Cancer Anaemia Survey. Oncology 2006;70:34-48.
2 Pirker R, Pirolli M, Quigley J, Hulnick S, Legg J, Collins H, et al. Hemoglobin decline in cancer patients receiving chemotherapy without an erythropoiesis-stimulating agent. Support Care Cancer 2013;21:987-92.
3 Kosmidis P, Krzakowski M. ECAS Investigators. Anemia profiles in patients with lung cancer: What have we learned from the European cancer anaemia survey (ECAS)? Lung Cancer 2005;50:401-12.
4 Platzbecker U, Hofbauer LC, Ehninger G, Hölig K. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res 2012;36:525-36.
5 Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13 Suppl 3:33-6.
6 Yarbro CH, Frogge MH, Goodman M. editors. Cancer Nursing: Principles and Practice 6^th ed. Sudbury, MA: Jones and Bartlett; 2005.
7 Gabrilove JL, Perez EA, Tomita DK, Rossi G, Cleeland CS. Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapy-induced anemia: Results of a multicenter, open-label study (SURPASS) of patients treated with darbepoetin-alpha at a dose of 200 microg every 2 weeks. Cancer 2007;110:1629-40.
8 van Weert E, Hoekstra-Weebers J, Otter R, Postema K, Sanderman R, van der Schans C, et al. Cancer-related fatigue: Predictors and effects of rehabilitation. Oncologist 2006;11:184-96.
9 National Comprehensive Cancer Network. Cancer-and Chemotherapy-Induced Anemia. Available from: http//www.nccn.org. [Last retrieved on 2009 Mar 21].
10 National Comprehensive Cancer Network. Cancer-Related Fatigue. Available from: http://www.nccn.org. [Last retrieved on 2009 Mar 21].
11 Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-49.
12 Canon JL, Vansteenkiste J, Bodoky G, Mateos MV, Bastit L, Ferreira I, et al. Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84.
13 Bastit L, Vandebroek A, Altintas S, Gaede B, Pintér T, Suto TS, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-8.
14 Steinmetz T, Schröder J, Plath M, Link H, Vogt M, Frank M, et al. Antianemic treatment of cancer patients in German routine practice: Data from a prospective cohort study-the tumor anemia registry. Anemia 2016;2016:8057650.
15 Available from: https://www.cresp.in/pdf/PI.pdf. [Last accessed on 2017 Dec 17].
16 Available from: http://www.drreddys.com/media/press-releases/aug9_2010.html. [Last accessed on 2017 Dec 17].
17 Birgegård G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, et al. Cancer-related anemia: Pathogenesis, prevalence and treatment. Oncology 2005;68 Suppl 1:3-11.
18 Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, et al. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist 2007;12:1253-63.
19 Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010;28:4996-5010.
20 Smith SW, Sato M, Gore SD, Baer MR, Ke X, McNally D, et al. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica 2012;97:15-20.
21 Harnan S, Ren S, Gomersall T, Everson-Hock ES, Sutton A, Dhanasiri S, et al. Association between transfusion status and overall survival in patients with myelodysplastic syndromes: A systematic literature review and meta-analysis. Acta Haematol 2016;136:23-42.
22 Revicki DA, Stull D, Vernon M, Rader M, Tomita D, Viswanathan HN, et al. Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials. Qual Life Res 2012;21:311-21.
23 Gordon D, Nichols G, Ben-Jacob A, Tomita D, Lillie T, Miller C, et al. Treating anemia of cancer with every-4-week darbepoetin alfa: Final efficacy and safety results from a phase II, randomized, double-blind, placebo-controlled study. Oncologist 2008;13:715-24.
24 Zachariah M, Elshinawy M, Alrawas A, Bashir W, Elbeshlawi I, Tony S, et al. Single dose darbepoetin alfa is useful in reducing red cell transfusions in leukemic children receiving chemotherapy. Pediatr Hematol Oncol 2014;31:442-7.
25 Vansteenkiste J, Wauters I, Elliott S, Glaspy J, Hedenus M. Chemotherapy-induced anemia: The story of darbepoetin alfa. Curr Med Res Opin 2013;29:325-37.
26 Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, et al. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: Study-level and patient-level meta-analyses. Lung Cancer 2012;76:478-85.
27 Nitz U, Gluz O, Zuna I, Oberhoff C, Reimer T, Schumacher C, et al. Final results from the prospective phase III WSG-ARA trial: Impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer. Ann Oncol 2014;25:75-80.
28 Ohashi Y, Uemura Y, Fujisaka Y, Sugiyama T, Ohmatsu H, Katsumata N, et al. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials. Cancer Sci 2013;104:481-5.
29 Bohlius J, Tonia T, Nüesch E, Jüni P, Fey MF, Egger M, et al. Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: Systematic review and meta-analyses of published and unpublished data. Br J Cancer 2014;111:33-45.
30 Van Belle S, Swieboda-Sadlej A, Karanikiotis C, Labourey JL, Galid A, Wheeler T, et al. A final analysis from the CHOICE study examining darbepoetin alfa use for chemotherapy-induced Anaemia in current European clinical practice. Curr Med Res Opin 2012;28:1079-87.
31 Motola D, Vaccheri A, Roncadori A, Donati M, Bonaldo G, Covezzoli A, et al. Comparative risk/benefit profile of biosimilar and originator erythropoiesis-stimulating agents (ESAs): Data from an Italian observational study in nephrology. Eur J Clin Pharmacol 2018;74:805-10.
32 Duran A, Spaepen E, Lamotte M, Walter E, Umuhire D, Lucioni C, et al. Cost analysis: Treatment of chemotherapy-induced anemia with erythropoiesis-stimulating agents in five European countries. J Med Econ 2012;15:409-18.